Centre for Health and Clinical Research, University of the West of England, and University Hospitals and Weston NHS Foundation Trust, Bristol, UK.
National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland, USA.
Ann Rheum Dis. 2022 Mar;81(3):315-320. doi: 10.1136/annrheumdis-2021-221795. Epub 2022 Feb 2.
To develop and validate revised classification criteria for granulomatosis with polyangiitis (GPA).
Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in five phases: (1) identification of candidate criteria items using consensus methodology, (2) prospective collection of candidate items present at the time of diagnosis, (3) data-driven reduction of the number of candidate items, (4) expert panel review of cases to define the reference diagnosis and (5) derivation of a points-based risk score for disease classification in a development set using least absolute shrinkage and selection operator logistic regression, with subsequent validation of performance characteristics in an independent set of cases and comparators.
The development set for GPA consisted of 578 cases of GPA and 652 comparators. The validation set consisted of an additional 146 cases of GPA and 161 comparators. From 91 candidate items, regression analysis identified 26 items for GPA, 10 of which were retained. The final criteria and their weights were as follows: bloody nasal discharge, nasal crusting or sino-nasal congestion (+3); cartilaginous involvement (+2); conductive or sensorineural hearing loss (+1); cytoplasmic antineutrophil cytoplasmic antibody (ANCA) or anti-proteinase 3 ANCA positivity (+5); pulmonary nodules, mass or cavitation on chest imaging (+2); granuloma or giant cells on biopsy (+2); inflammation or consolidation of the nasal/paranasal sinuses on imaging (+1); pauci-immune glomerulonephritis (+1); perinuclear ANCA or antimyeloperoxidase ANCA positivity (-1); and eosinophil count ≥1×10 /L (-4). After excluding mimics of vasculitis, a patient with a diagnosis of small- or medium-vessel vasculitis could be classified as having GPA if the cumulative score was ≥5 points. When these criteria were tested in the validation data set, the sensitivity was 93% (95% CI 87% to 96%) and the specificity was 94% (95% CI 89% to 97%).
The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for GPA demonstrate strong performance characteristics and are validated for use in research.
制定并验证肉芽肿性多血管炎(GPA)修订分类标准。
将血管炎或对照疾病患者纳入国际队列。研究分五个阶段进行:(1)使用共识方法确定候选标准项目,(2)前瞻性收集诊断时存在的候选项目,(3)基于数据减少候选项目数量,(4)专家小组审查病例以定义参考诊断,(5)使用最小绝对收缩和选择算子逻辑回归为开发集中的疾病分类制定基于分数的风险评分,随后在独立的病例和对照集中验证性能特征。
GPA 的开发集由 578 例 GPA 病例和 652 例对照组成。验证集由另外 146 例 GPA 病例和 161 例对照组成。从 91 项候选项目中,回归分析确定了 26 项 GPA 项目,其中 10 项保留。最终标准及其权重如下:血性鼻分泌物、鼻结痂或鼻-鼻窦充血(+3);软骨受累(+2);传导性或感觉神经性听力损失(+1);细胞质抗中性粒细胞胞质抗体(ANCA)或抗蛋白酶 3 ANCA 阳性(+5);胸部影像学上有肺结节、肿块或空洞(+2);活检有肉芽肿或巨细胞(+2);影像学上鼻/副鼻窦有炎症或实变(+1);少免疫性肾小球肾炎(+1);核周 ANCA 或抗髓过氧化物酶 ANCA 阳性(-1);嗜酸性粒细胞计数≥1×10/L(-4)。排除血管炎的模拟物后,如果小或中血管炎患者的累积评分≥5 分,则可诊断为 GPA。当这些标准在验证数据集进行测试时,敏感性为 93%(95%CI 87%至 96%),特异性为 94%(95%CI 89%至 97%)。
2022 年美国风湿病学会/欧洲风湿病联盟 GPA 分类标准具有良好的性能特征,并经过验证可用于研究。